Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    July 2021
  1. UGAI T, Vayrynen JP, Haruki K, Akimoto N, et al
    Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321960. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  2. TEN HOORN S, de Back TR, Sommeijer DW, Vermeulen L, et al
    Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2021 Jun 2. pii: 6291249. doi: 10.1093.
    PubMed     Abstract available


  3. YIN J, Cohen R, Jin Z, Liu H, et al
    Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    J Natl Cancer Inst. 2021 Jun 1. pii: 6290718. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  4. RANDON G, Yaeger R, Hechtman JF, Manca P, et al
    EGFR Amplification in Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2021 Apr 7. pii: 6213909. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  5. WANG K, Ma W, Wu K, Ogino S, et al
    Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles.
    J Natl Cancer Inst. 2021 Mar 18. pii: 6178004. doi: 10.1093.
    PubMed     Abstract available


  6. DEMB JB, Gupta S
    Realizing the Promise of Personalized Colorectal Cancer Screening in Practice.
    J Natl Cancer Inst. 2021 Mar 18. pii: 6178006. doi: 10.1093.
    PubMed    


  7. COHEN R, Liu H, Fiskum J, Adams R, et al
    BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database.
    J Natl Cancer Inst. 2021 Mar 18. pii: 6178005. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  8. MCNEIL JJ
    Aspirin and primary prevention of colorectal cancer: a still evolving story.
    J Natl Cancer Inst. 2021 Feb 2. pii: 6123750. doi: 10.1093.
    PubMed    


  9. ZHANG Y, Chan AT, Meyerhardt JA, Giovannucci EL, et al
    Timing of aspirin use in colorectal cancer chemoprevention: a prospective cohort study.
    J Natl Cancer Inst. 2021 Feb 2. pii: 6123749. doi: 10.1093.
    PubMed     Abstract available


  10. FIGUEIREDO JC, Jacobs EJ, Newton CC, Guinter MA, et al
    Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis.
    J Natl Cancer Inst. 2021 Feb 2. pii: 6123748. doi: 10.1093.
    PubMed     Abstract available


  11. RANSOHOFF DF
    Evaluating a New Cancer Screening Blood Test: Unintended Consequences and the Need for Clarity in Policy Making.
    J Natl Cancer Inst. 2021;113:109-111.
    PubMed    


    January 2021
  12. HOWREN A, Sayre EC, Loree JM, Gill S, et al
    Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: A population-based longitudinal study.
    J Natl Cancer Inst. 2021 Jan 25. pii: 6119347. doi: 10.1093.
    PubMed     Abstract available


  13. FEDEWA SA, Anderson JC, Siegel RL
    Colorectal Cancer incidence in Canada: what do rates at age 50 years reflect?
    J Natl Cancer Inst. 2021 Jan 25. pii: 6119348. doi: 10.1093.
    PubMed    


    December 2020
  14. JOSHI AD, Chan AT
    Racial differences in epigenetic aging of the colon: Implications for colorectal cancer.
    J Natl Cancer Inst. 2020 Dec 30. pii: 6055552. doi: 10.1093.
    PubMed    


    November 2020
  15. SNYDER RA, Hu CY, Zafar SN, Francescatti A, et al
    Racial Disparities in Recurrence and Overall Survival in Patients with Locoregional Colorectal Cancer.
    J Natl Cancer Inst. 2020 Nov 24. pii: 5999805. doi: 10.1093.
    PubMed     Abstract available


  16. MANZ CR, Schrag D
    Racial disparities in colorectal cancer recurrence and mortality: equitable care, inequitable outcomes?
    J Natl Cancer Inst. 2020 Nov 24. pii: 5999804. doi: 10.1093.
    PubMed    


  17. ZHENG X, Hur J, Nguyen LH, Liu J, et al
    Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer.
    J Natl Cancer Inst. 2020 Nov 2. pii: 5951179. doi: 10.1093.
    PubMed     Abstract available


  18. MURPHY N, Campbell PT, Gunter MJ
    Unravelling the etiology of early-onset colorectal cancer.
    J Natl Cancer Inst. 2020 Nov 2. pii: 5951177. doi: 10.1093.
    PubMed    


    September 2020
  19. ALDERSON PO, Summers RM
    The Evolving Status of Radiomics.
    J Natl Cancer Inst. 2020;112:869-870.
    PubMed    


    August 2020

  20. Corrigendum: Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study.
    J Natl Cancer Inst. 2020 Aug 28. pii: 5898367. doi: 10.1093.
    PubMed    


  21. WAGNER AD, Grothey A, Andre T, Dixon JG, et al
    Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.
    J Natl Cancer Inst. 2020 Aug 24. pii: 5896535. doi: 10.1093.
    PubMed     Abstract available


  22. NODORA JN, Gupta S, Howard N, Motadel K, et al
    The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities.
    J Natl Cancer Inst. 2020 Aug 11. pii: 5891177. doi: 10.1093.
    PubMed     Abstract available


  23. PETERSE EFP, Meester RGS, de Jonge L, Omidvari AH, et al
    Comparing the cost-effectiveness of innovative colorectal cancer screening tests.
    J Natl Cancer Inst. 2020 Aug 6. pii: 5882024. doi: 10.1093.
    PubMed     Abstract available


  24. ROMESSER PB, Smith G, Crane CH
    Nonoperative Management of Rectal Cancer Shows Cost-Effectiveness, but Can Comparative Effectiveness Be Established?
    J Natl Cancer Inst. 2020;112:771-772.
    PubMed    


    May 2020
  25. ZAANAN A, Henriques J, Cohen R, Sefrioui D, et al
    Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin.
    J Natl Cancer Inst. 2020 May 16. pii: 5838189. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  26. NGEOW J, Eng C
    Oh GxE! The Complexity of Body Mass Index and Colon Cancer Risk.
    J Natl Cancer Inst. 2020 Apr 23. pii: 5824299. doi: 10.1093.
    PubMed    


  27. CAMPBELL PT, Lin Y, Bien SA, Figueiredo JC, et al
    Association of body mass index with colorectal cancer risk by genome-wide variants.
    J Natl Cancer Inst. 2020 Apr 23. pii: 5824300. doi: 10.1093.
    PubMed     Abstract available


  28. LUDFORD K, Cohen R, Svrcek M, Foo WC, et al
    Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer.
    J Natl Cancer Inst. 2020 Apr 15. pii: 5820518. doi: 10.1093.
    PubMed     Abstract available


  29. OH M, McBride A, Yun S, Bhattacharjee S, et al
    Response to Yang, Shi, Wang et al.
    J Natl Cancer Inst. 2020;112:428.
    PubMed    


    March 2020
  30. GULHATI P, Yin J, Pederson L, Schmoll HJ, et al
    Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA.
    J Natl Cancer Inst. 2020 Mar 19. pii: 5810087. doi: 10.1093.
    PubMed     Abstract available


  31. DE KONING HJ
    The Future Is Prosperous.
    J Natl Cancer Inst. 2020;112:219-220.
    PubMed    


    February 2020
  32. CHANG GJ, You YNY, Russell CA, Tierno MB, et al
    Young-Onset Colon Cancer and Recurrence Risk By Gene Expression.
    J Natl Cancer Inst. 2020 Feb 10. pii: 5732656. doi: 10.1093.
    PubMed     Abstract available


  33. DERCLE L, Lu L, Schwartz LH, Qian M, et al
    Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
    J Natl Cancer Inst. 2020 Feb 4. pii: 5722208. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  34. NOGUEIRA L, Chawla N, Han X, Jemal A, et al
    Colorectal Cancer Care among Young Adult Patients after the Dependent Coverage Expansion under the Affordable Care Act.
    J Natl Cancer Inst. 2019 Dec 19. pii: 5679791. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  35. KUHN T, Stepien M, Lopez-Nogueroles M, Machado AD, et al
    Pre-diagnostic plasma bile acid levels and colon cancer risk: A prospective study.
    J Natl Cancer Inst. 2019 Aug 21. pii: 5552558. doi: 10.1093.
    PubMed     Abstract available


  36. YANG H, Shi L, Wang Y, Duan G, et al
    RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2019 Aug 19. pii: 5551341. doi: 10.1093.
    PubMed    


    July 2019
  37. BROWN JC, Caan BJ, Prado CM, Feliciano EMC, et al
    The Association of Abdominal Adiposity with Mortality in Patients with Stage I-III Colorectal Cancer.
    J Natl Cancer Inst. 2019 Jul 29. pii: 5537700. doi: 10.1093.
    PubMed     Abstract available


  38. BARLOW WE, Beaber EF, Geller BM, Kamineni A, et al
    Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.
    J Natl Cancer Inst. 2019 Jul 11. pii: 5530599. doi: 10.1093.
    PubMed     Abstract available


  39. EAGLEHOUSE YL, Georg MW, Shriver CD, Zhu K, et al
    Racial Comparisons in Timeliness of Colon Cancer Treatment in an Equal-Access Health System.
    J Natl Cancer Inst. 2019 Jul 4. pii: 5528256. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  40. SOMSOUK M, Rachocki C, Mannalithara A, Garcia D, et al
    Effectiveness and cost of organized outreach for colorectal cancer screening: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2019 Jun 12. pii: 5513785. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  41. SIEGEL RL, Medhanie GA, Fedewa SA, Jemal A, et al
    State variation in early-onset colorectal cancer in the United States, 1995-2015.
    J Natl Cancer Inst. 2019 May 29. pii: 5498152. doi: 10.1093.
    PubMed     Abstract available


  42. FRANKE AJ, Skelton WP, Starr JS, Parekh H, et al
    Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
    J Natl Cancer Inst. 2019 May 20. pii: 5492079. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  43. GINI A, Meester RGS, Keshavarz H, Oeffinger KC, et al
    Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2019 Apr 13. pii: 5454689. doi: 10.1093.
    PubMed     Abstract available


  44. TEEPEN JC, Ronckers CM, Kremer LCM
    Colorectal Cancer Screening in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2019 Apr 9. pii: 5454690. doi: 10.1093.
    PubMed    


    March 2019
  45. HAWKINS ML, Blackburn BE, Rowe K, Snyder J, et al
    Endocrine and Metabolic Diseases among Colorectal Cancer Survivors in a Population-Based Cohort.
    J Natl Cancer Inst. 2019 Mar 27. pii: 5421169. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  46. KATONA BW, Stadler ZK, Robson ME, Domchek SM, et al
    RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2019 Feb 4. pii: 5305034. doi: 10.1093.
    PubMed    


    January 2019
  47. GRAY V, Briggs S, Palles C, Jaeger E, et al
    Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
    J Natl Cancer Inst. 2019 Jan 14. pii: 5289445. doi: 10.1093.
    PubMed     Abstract available


    December 2018
  48. JU HQ, Lu YX, Chen DL, Zuo ZX, et al
    Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    J Natl Cancer Inst. 2018 Dec 8. pii: 5236681. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  49. BARRY EL, Fedirko V, Baron JA
    NSAIDs and Colorectal Cancer Phenotypes: What Now?
    J Natl Cancer Inst. 2018 Nov 2. pii: 5156227. doi: 10.1093.
    PubMed    


  50. AMITAY EL, Carr PR, Jansen L, Walter V, et al
    Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
    J Natl Cancer Inst. 2018 Nov 2. pii: 5156228. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  51. OH M, McBride A, Yun S, Bhattacharjee S, et al
    BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Oct 31. pii: 5151259. doi: 10.1093.
    PubMed     Abstract available


  52. CHOI YH, Lakhal-Chaieb L, Krol A, Yu B, et al
    Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families.
    J Natl Cancer Inst. 2018 Oct 30. pii: 5149368. doi: 10.1093.
    PubMed     Abstract available


  53. HAMADA T, Nowak JA, Masugi Y, Drew DA, et al
    Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127125. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  54. MORALES-OYARVIDE V, Yuan C, Babic A, Zhang S, et al
    Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
    J Natl Cancer Inst. 2018 Jun 21. pii: 5038128. doi: 10.1093.
    PubMed     Abstract available


  55. SCHMIT SL, Edlund CK, Schumacher FR, Gong J, et al
    Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
    J Natl Cancer Inst. 2018 Jun 16. pii: 5039592. doi: 10.1093.
    PubMed     Abstract available


  56. MCCULLOUGH ML, Zoltick ES, Weinstein SJ, Fedirko V, et al
    Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts.
    J Natl Cancer Inst. 2018 Jun 14. pii: 5035027. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  57. LOREE JM, Bailey AM, Johnson AM, Yu Y, et al
    Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
    J Natl Cancer Inst. 2018 Apr 27. pii: 4989438. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  58. CIVES M, Anaya DA, Soares H, Coppola D, et al
    Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors.
    J Natl Cancer Inst. 2018;110:282-289.
    PubMed     Abstract available


    February 2018
  59. COGHILL AE, Engels EA, Schymura MJ, Mahale P, et al
    Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States.
    J Natl Cancer Inst. 2018 Feb 26. pii: 4911376. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  60. ARAGHI M, Fidler MM, Arnold M, Jemal A, et al
    The Future Burden of Colorectal Cancer Among US Blacks and Whites.
    J Natl Cancer Inst. 2018 Jan 23. pii: 4822521. doi: 10.1093.
    PubMed     Abstract available


  61. MARISA L, Svrcek M, Collura A, Becht E, et al
    The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  62. MLECNIK B, Van den Eynde M, Bindea G, Church SE, et al
    Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  63. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  64. HANLEY CJ, Mellone M, Ford K, Thirdborough SM, et al
    Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    December 2017
  65. SJOQUIST KM, Renfro LA, Simes RJ, Tebbutt NC, et al
    Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
    J Natl Cancer Inst. 2017 Dec 18. pii: 4757465. doi: 10.1093.
    PubMed     Abstract available


  66. FOKAS E, Strobel P, Fietkau R, Ghadimi M, et al
    Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  67. PIETRANTONIO F, Di Nicolantonio F, Schrock AB, Lee J, et al
    ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    August 2017
  68. MURPHY CC, Sanoff HK, Stitzenberg KB, Baron JA, et al
    RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.
    J Natl Cancer Inst. 2017;109.
    PubMed    


  69. MOLENAAR RJ, Radivoyevitch T, Wilmink JW
    RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.
    J Natl Cancer Inst. 2017;109.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: